Press Release

Date: September 17, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 544558 Dear Sir/Madam, Sub: Press Release Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”) Pursuant to the aforementioned Regulation, we hereby enclose a copy of the Press Release titled “Fabtech Technologies Ltd enters CIS Country with New Turnkey Design-and-Build Project”. The above can also be accessed on the website of the Company at www.fabtechnologies.com We request you to take the above information on record. Thank you. Yours faithfully, For Fabtech Technologies Limited Hemant Mohan Anavkar Executive Director DIN: 00150776 Encl.: As mentioned above Fabtech Technologies Ltd Fabtech Technologies Ltd enters CIS Country with New Turnkey Design-and-Build Project Mumbai | 17 September, 2026: Fabtech Technologies Limited, a global provider of integrated design, engineering and build solutions for regulated manufacturing environments, has secured a INR 21 crore turnkey project in a CIS Country. The order marks Fabtech’s entry into this CIS market and expands the Company’s international execution footprint into a technically demanding geography. The project involves the development of critical internal infrastructure for an advanced medical-device manufacturing facility. Fabtech's scope includes integrated engineering and design, cleanroom systems, HVAC, building management systems, electrical systems, process and clean utilities, laboratory and cleanroom furniture, fire and life-safety systems, installation, testing and commissioning. Process manufacturing equipment will be sourced directly by the customer, with Fabtech engineering the infrastructure required for seamless integration. A defining feature of the mandate is its climate-responsive engineering. The facility is being designed for the CIS country's operating conditions, requiring specific selection of materials, HVAC architecture, utilities and insulation to maintain controlled manufacturing conditions through severe seasonal temperature variations. The project therefore goes beyond conventional cleanroom execution, combining environmental control, utility reliability and equipment-interface engineering within a coordinated design- and-build programme. The end user operates in the global medical-technology sector, where manufacturing environments require high levels of control, repeatability and infrastructure reliability. The project reinforces Fabtech’s ability to translate such requirements into compliant, execution-ready facilities while adapting its engineering platform to local climatic and operating conditions. The project is targeted for handover within approximately 12 months from completion and availability of the civil front. Execution will span engineering and design, procurement and manufacturing, FAT and inspection, logistics, installation, testing and commissioning, and qualification/validation activities as applicable. Strategically, the order opens a new geography for Fabtech while demonstrating the portability of its integrated Design-Engineer-Build model across markets with materially different climatic, regulatory and infrastructure conditions. The entry into this CIS country further strengthens Fabtech’s growing international business and its positioning as a single-point partner for complex, regulated manufacturing infrastructure. Mr. Aman Anavkar, Chief Growth Officer, Fabtech Technologies Limited, said: “Entering CIS country through a project of this technical complexity is an important milestone for Fabtech. The mandate is not simply to supply infrastructure, but to engineer a manufacturing environment around the process, the local climate and the customer’s long-term operating requirements. Bringing design, utilities, cleanroom systems, HVAC, electrical integration and validation thinking under one execution framework is central to the value we bring to this project.” About Fabtech Technologies Ltd, Fabtech Technologies Limited is a pharmaceutical engineering company providing specialised engineering, technology and turnkey solutions (including Design & Build) to the pharmaceutical, biotechnology and healthcare sectors. Over the past 25 years, Fabtech has developed capabilities across project design, technology transfer, pharmaceutical equipment manufacturing, turnkey project management, cleanroom infrastructure, cleanroom partitions and HVAC, containment solutions, pharmaceutical MEP, clean utilities, process piping, purified water systems and water-for injection systems. The company has executed 750+ projects across 62 countries, supported by a global workforce of 650+ professionals and regional operations across markets including the UAE, Saudi Arabia, Egypt, Nigeria, the UK, Algeria and Sri Lanka. With more than two decades of experience in pharmaceutical engineering, Fabtech has built capabilities spanning turnkey project management, cleanroom infrastructure, pharmaceutical MEP, process engineering, clean utilities, containment solutions and specialised pharmaceutical equipment. The company has executed projects across multiple geographies and continues to strengthen its international engineering and execution footprint. As pharmaceutical manufacturing capacity expands across emerging markets, Fabtech Technologies remains focused on leveraging its engineering expertise, international presence and execution capabilities to participate in the next phase of global healthcare infrastructure development. For further information, please contact KAPTIFY Consulting Fabtech Technologies Ltd. Investor Relations | Strategy | Consulting E: cs@fabtechnologies.com E: contact@kaptify.in | M: +91-845 288 6099 www.fabtechnologies.com www.kaptify.in Disclaimer This document may contain certain forward-looking statements within the meaning of applicable securities law and regulations. These statements include descriptions regarding the intent, belief or current expectations of the Company or its directors and officers with respect to the results of operations and financial condition of the Company. Such forward‐looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in such forward‐looking statements as a result of various factors and assumptions which the Company believes to be reasonable in light of its operating experience in recent years. Many factors could cause the actual results, performances, or achievements of the Company to be materially different from any future results, performances, or achievements. Significant factors that could make a difference to the Company’s operations include domestic and international economic conditions, changes in government regulations, tax regime and other statutes. The Company does not undertake to revise any forward‐ looking statement that may be made from time to time by or on behalf of the Company.